Nature:特异肠道微生物亚群暗示渐冻症未来治疗新途径

2019-07-24 纪大乙 生物探索

肌萎缩侧索硬化症(ALS),俗称“渐冻症”,是一种神经退行性疾病,影响患者脊髓和大脑中与运动相关的神经,导致运动神经元逐渐萎缩并死亡,令大脑无法控制肌肉运动。大多数患者在确诊后只有3-5年的生存期。去年陨世的著名物理学家斯蒂芬?霍金在21岁时即被诊断患有此症。

肌萎缩侧索硬化症(ALS),俗称“渐冻症”,是一种神经退行性疾病,影响患者脊髓和大脑中与运动相关的神经,导致运动神经元逐渐萎缩并死亡,令大脑无法控制肌肉运动。大多数患者在确诊后只有3-5年的生存期。去年陨世的著名物理学家斯蒂芬?霍金在21岁时即被诊断患有此症。

2014年夏天,“冰桶挑战”风靡一时,越来越多的普通人开始了解和关注ALS。一直以来,科研工作者从未停止对ALS的探寻,希望有朝一日能够为ALS“解冻”。近日,发表在《Nature》上的一篇重磅研究表明,肠道微生物组或能影响ALS进程,该研究也将为ALS的治疗提供新的方向。

越来越多的证据表明,肠道菌群与多种大脑功能和疾病相关。比如帕金森病(Neuron:帕金森病起源于肠道,通过神经传入大脑)、压力和焦虑(压力、焦虑,你怕了吗?2篇新研究:看肠道菌群如何来刷“存在感”)、多发性硬化(MS)(肠道微生物保护神经免受病毒感染伤害)等。

于是来自德国癌症研究中心(DKFZ)和以色列魏茨曼科学研究院(Weizmann Institute of Science)的一支科研合作团队试图探究肠道菌群在ALS的潜在作用。

肠道菌群与ALS进程相关

起初,研究人员通过一系列探索性实验证明,在转基因小鼠中使用广谱抗生素清除其大部分菌群后,一种类似ALS的疾病症状会恶化。这一结果暗示了菌群的改变与遗传上易患ALS的小鼠疾病加速发展之间的潜在联系。那么到底是哪种微生物在作祟呢?

于是,研究人员利用先进的计算方法对ALS易感小鼠体内微生物组的组成和功能进行了表征,并与正常小鼠进行了比较。由此,研究人员最终鉴定出11种微生物菌株。这些菌株在易感ALS的小鼠中随着疾病的进展而发生变化,甚至在小鼠出现明显的ALS症状之前就发生了变化。

接下来,研究人员将这些菌株分离出来,并在抗生素治疗后以类似益生菌补充物的形式,一个接一个地给易感ALS小鼠服用,其中一些菌株对这种类似ALS的疾病产生了明显的负面影响。但有一种叫嗜黏蛋白阿克曼氏菌(Akkermansia muciniphila)的菌株显着减缓了小鼠的疾病进展,延长了它们的生存周期。

嗜黏蛋白阿克曼氏菌

为了揭示嗜黏蛋白阿克曼氏菌产生这种效果的机理,研究人员检测了肠道微生物分泌的数千个小分子。最终将注意力集中在一种叫做烟酰胺(NAM)的分子上:抗生素治疗后,易感ALS小鼠血液和脑脊液中的烟酰胺水平降低,而在补充了能够分泌这种分子的嗜黏蛋白阿克曼氏菌后,烟酰胺水平升高。

为了证实NAM确实是一种由微生物分泌的能够阻碍ALS进程的分子,研究人员向ALS小鼠补充NAM后发现,这些小鼠的临床状况明显得到改善。进一步对这些小鼠的大脑中基因表达分析表明,NAM改善了运动神经元的功能。

人体研究

为了探究NAM是否在人体中也有如此功效,研究人员进行了一项小型人体研究(37位ALS患者和29位对照并也观察到类似的结果,即ALS患者的肠道菌群发生改变,部分ALS患者的血液和脑脊液中,NAM水平也下降。

结语

总的来说,这项研究的结果表明,肠道菌群对ALS具有潜在作用,这一发现或能为将来识别可修饰的治疗靶标铺平道路。

研究者表示该结论还需要开展更多规模的前瞻性队列研究加以验证。

原始出处:
Blacher E1, Bashiardes S1, Shapiro H1, et al.Potential roles of gut microbiome and metabolites in modulating ALS in mice.Nature. 2019 Jul 22. doi: 10.1038/s41586-019-1443-5. [Epub ahead of print]

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1953390, encodeId=69e01953390a2, content=<a href='/topic/show?id=edbb58e115a' target=_blank style='color:#2F92EE;'>#新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58711, encryptionId=edbb58e115a, topicName=新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Wed Oct 30 04:19:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1825067, encodeId=eb21182506e90, content=<a href='/topic/show?id=702a5065860' target=_blank style='color:#2F92EE;'>#微生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50658, encryptionId=702a5065860, topicName=微生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Thu Feb 27 01:19:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883783, encodeId=df1a1883e83af, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Aug 07 13:19:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949426, encodeId=f921194942679, content=<a href='/topic/show?id=7ac6646456f' target=_blank style='color:#2F92EE;'>#治疗新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64645, encryptionId=7ac6646456f, topicName=治疗新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Wed Jul 24 17:19:00 CST 2019, time=2019-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269698, encodeId=d1af1269698fe, content=<a href='/topic/show?id=5e106628237' target=_blank style='color:#2F92EE;'>#渐冻症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66282, encryptionId=5e106628237, topicName=渐冻症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Jul 26 06:19:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370208, encodeId=09793e02084a, content=向挑战病魔的科研人员致敬!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Wed Jul 24 16:22:54 CST 2019, time=2019-07-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1953390, encodeId=69e01953390a2, content=<a href='/topic/show?id=edbb58e115a' target=_blank style='color:#2F92EE;'>#新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58711, encryptionId=edbb58e115a, topicName=新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Wed Oct 30 04:19:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1825067, encodeId=eb21182506e90, content=<a href='/topic/show?id=702a5065860' target=_blank style='color:#2F92EE;'>#微生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50658, encryptionId=702a5065860, topicName=微生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Thu Feb 27 01:19:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883783, encodeId=df1a1883e83af, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Aug 07 13:19:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949426, encodeId=f921194942679, content=<a href='/topic/show?id=7ac6646456f' target=_blank style='color:#2F92EE;'>#治疗新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64645, encryptionId=7ac6646456f, topicName=治疗新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Wed Jul 24 17:19:00 CST 2019, time=2019-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269698, encodeId=d1af1269698fe, content=<a href='/topic/show?id=5e106628237' target=_blank style='color:#2F92EE;'>#渐冻症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66282, encryptionId=5e106628237, topicName=渐冻症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Jul 26 06:19:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370208, encodeId=09793e02084a, content=向挑战病魔的科研人员致敬!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Wed Jul 24 16:22:54 CST 2019, time=2019-07-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1953390, encodeId=69e01953390a2, content=<a href='/topic/show?id=edbb58e115a' target=_blank style='color:#2F92EE;'>#新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58711, encryptionId=edbb58e115a, topicName=新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Wed Oct 30 04:19:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1825067, encodeId=eb21182506e90, content=<a href='/topic/show?id=702a5065860' target=_blank style='color:#2F92EE;'>#微生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50658, encryptionId=702a5065860, topicName=微生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Thu Feb 27 01:19:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883783, encodeId=df1a1883e83af, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Aug 07 13:19:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949426, encodeId=f921194942679, content=<a href='/topic/show?id=7ac6646456f' target=_blank style='color:#2F92EE;'>#治疗新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64645, encryptionId=7ac6646456f, topicName=治疗新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Wed Jul 24 17:19:00 CST 2019, time=2019-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269698, encodeId=d1af1269698fe, content=<a href='/topic/show?id=5e106628237' target=_blank style='color:#2F92EE;'>#渐冻症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66282, encryptionId=5e106628237, topicName=渐冻症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Jul 26 06:19:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370208, encodeId=09793e02084a, content=向挑战病魔的科研人员致敬!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Wed Jul 24 16:22:54 CST 2019, time=2019-07-24, status=1, ipAttribution=)]
    2019-08-07 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=1953390, encodeId=69e01953390a2, content=<a href='/topic/show?id=edbb58e115a' target=_blank style='color:#2F92EE;'>#新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58711, encryptionId=edbb58e115a, topicName=新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Wed Oct 30 04:19:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1825067, encodeId=eb21182506e90, content=<a href='/topic/show?id=702a5065860' target=_blank style='color:#2F92EE;'>#微生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50658, encryptionId=702a5065860, topicName=微生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Thu Feb 27 01:19:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883783, encodeId=df1a1883e83af, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Aug 07 13:19:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949426, encodeId=f921194942679, content=<a href='/topic/show?id=7ac6646456f' target=_blank style='color:#2F92EE;'>#治疗新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64645, encryptionId=7ac6646456f, topicName=治疗新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Wed Jul 24 17:19:00 CST 2019, time=2019-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269698, encodeId=d1af1269698fe, content=<a href='/topic/show?id=5e106628237' target=_blank style='color:#2F92EE;'>#渐冻症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66282, encryptionId=5e106628237, topicName=渐冻症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Jul 26 06:19:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370208, encodeId=09793e02084a, content=向挑战病魔的科研人员致敬!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Wed Jul 24 16:22:54 CST 2019, time=2019-07-24, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1953390, encodeId=69e01953390a2, content=<a href='/topic/show?id=edbb58e115a' target=_blank style='color:#2F92EE;'>#新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58711, encryptionId=edbb58e115a, topicName=新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Wed Oct 30 04:19:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1825067, encodeId=eb21182506e90, content=<a href='/topic/show?id=702a5065860' target=_blank style='color:#2F92EE;'>#微生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50658, encryptionId=702a5065860, topicName=微生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Thu Feb 27 01:19:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883783, encodeId=df1a1883e83af, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Aug 07 13:19:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949426, encodeId=f921194942679, content=<a href='/topic/show?id=7ac6646456f' target=_blank style='color:#2F92EE;'>#治疗新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64645, encryptionId=7ac6646456f, topicName=治疗新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Wed Jul 24 17:19:00 CST 2019, time=2019-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269698, encodeId=d1af1269698fe, content=<a href='/topic/show?id=5e106628237' target=_blank style='color:#2F92EE;'>#渐冻症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66282, encryptionId=5e106628237, topicName=渐冻症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Jul 26 06:19:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370208, encodeId=09793e02084a, content=向挑战病魔的科研人员致敬!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Wed Jul 24 16:22:54 CST 2019, time=2019-07-24, status=1, ipAttribution=)]
    2019-07-26 xjy02
  6. [GetPortalCommentsPageByObjectIdResponse(id=1953390, encodeId=69e01953390a2, content=<a href='/topic/show?id=edbb58e115a' target=_blank style='color:#2F92EE;'>#新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58711, encryptionId=edbb58e115a, topicName=新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Wed Oct 30 04:19:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1825067, encodeId=eb21182506e90, content=<a href='/topic/show?id=702a5065860' target=_blank style='color:#2F92EE;'>#微生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50658, encryptionId=702a5065860, topicName=微生物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0b7c20, createdName=wjcjjian, createdTime=Thu Feb 27 01:19:00 CST 2020, time=2020-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883783, encodeId=df1a1883e83af, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Aug 07 13:19:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949426, encodeId=f921194942679, content=<a href='/topic/show?id=7ac6646456f' target=_blank style='color:#2F92EE;'>#治疗新途径#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64645, encryptionId=7ac6646456f, topicName=治疗新途径)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Wed Jul 24 17:19:00 CST 2019, time=2019-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269698, encodeId=d1af1269698fe, content=<a href='/topic/show?id=5e106628237' target=_blank style='color:#2F92EE;'>#渐冻症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66282, encryptionId=5e106628237, topicName=渐冻症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Fri Jul 26 06:19:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370208, encodeId=09793e02084a, content=向挑战病魔的科研人员致敬!, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Wed Jul 24 16:22:54 CST 2019, time=2019-07-24, status=1, ipAttribution=)]
    2019-07-24 坚强007

    向挑战病魔的科研人员致敬!

    0